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Abstract
Background: The 15q24 microdeletion syndrome has been recently described as a recurrent, submicroscopic
genomic imbalance found in individuals with intellectual disability, typical facial appearance, hypotonia, and digital
and genital abnormalities. Gene dosage abnormalities, including copy number variations (CNVs), have been
identified in a significant fraction of individuals with autism spectrum disorders (ASDs). In this study we surveyed
two ASD cohorts for 15q24 abnormalities to assess the frequency of genomic imbalances in this interval.
Methods: We screened 173 unrelated subjects with ASD from the Central Valley of Costa Rica and 1336 subjects
with ASD from 785 independent families registered with the Autism Genetic Resource Exchange (AGRE) for CNVs
across 15q24 using oligonucleotide arrays. Rearrangements were confirmed by array comparative genomic
hybridization and quantitative PCR.
Results: Among the patients from Costa Rica, an atypical de novo deletion of 3.06 Mb in 15q23-q24.1 was
detected in a boy with autism sharing many features with the other 13 subjects with the 15q24 microdeletion
syndrome described to date. He exhibited intellectual disability, constant smiling, characteristic facial features (high
anterior hairline, broad medial eyebrows, epicanthal folds, hypertelorism, full lower lip and protuberant, posteriorly
rotated ears), single palmar crease, toe syndactyly and congenital nystagmus. The deletion breakpoints are atypical
and lie outside previously characterized low copy repeats (69,838-72,897 Mb). Genotyping data revealed that the
deletion had occurred in the paternal chromosome. Among the AGRE families, no large 15q24 deletions were
observed.
Conclusions: From the current and previous studies, deletions in the 15q24 region represent rare causes of ASDs
with an estimated frequency of 0.1 to 0.2% in individuals ascertained for ASDs, although the proportion might be
higher in sporadic cases. These rates compare with a frequency of about 0.3% in patients ascertained for
unexplained intellectual disability and congenital anomalies. This atypical deletion reduces the minimal interval for
the syndrome from 1.75 Mb to 766 kb, implicating a reduced number of genes (15 versus 38). Sequencing of
genes in the 15q24 interval in large ASD and intellectual disability samples may identify mutations of etiologic
importance in the development of these disorders.
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The widespread use of genomic DNA array-based tech-
nologies to detect whole genome copy number varia-
tions (CNVs) has led to the identification of novel
recurrent genomic disorders associated with syndromic
or nonsyndromic intellectual disability [1]. The 15q24
microdeletion syndrome was first described by Sharp
et al. in 2007 in four subjects sharing clinical character-
istics and overlapping de novo deletions [2]. Phenotypic
features include mild to moderate developmental delay,
characteristic facial features (high anterior hairline,
broad medial eyebrows, hypertelorism, downslanting
palpebral fissures, broad nasal base, long smooth phil-
trum, and full lower lip), growth retardation, hypotonia,
joint laxity, digital abnormalities and genital abnormal-
ities [2]. The recurrent deletions, ranging from 1.7 to
3.9 Mb, result from non-allelic homologous recombina-
tion mediated by low-copy repeat (LCR, also called seg-
mental duplication) clusters in 15q24, termed BP1, BP2
and BP3 [2]. Sharp et al. defined a minimal critical
region between BP1 and BP2 that spanned 1.75 Mb of
genomic sequence. More recently, El-Hattab et al. [3]
reported four additional deletion cases, which implicated
the same 1.75 Mb minimal critical region in the syn-
drome and described two other LCR clusters that med-
iate the formation of alternative-sized rearrangements,
termed LCR 15q24A, 15q24B (BP1), 15q24C, 15q24D
(BP2) and 15q24E (BP3). Three other subjects with
15q24 deletion have been reported recently, further
expanding the phenotypic spectrum [4-6]. In addition,
there have been four reported 15q24 duplications that
involve the same LCRs and share some clinical features
with cases of 15q24 microdeletion [3,7].
Genetic variants that present with developmental delay
can often be associated with an autism spectrum disor-
der (ASD). Smith et al. described a girl with autism,
developmental delay and mild dysmorphism carrying
what was first identified as an interstitial deletion of
chromosome 15q22-q23 according to fluorescent in situ
hybridization (FISH) analysis [8], but subsequent micro-
array mapping revealed to be a 15q24 deletion overlap-
ping the genomic region identified by Sharp et al. [2]
(Moyra Smith, personal communication). Furthermore,
a recent analysis of 427 unrelated subjects with ASD
reported a 15q24 de novo deletion in a boy with ASD,
intellectual disability, severe dysmorphism, scoliosis and
diaphragmatic hernia [9]. The deletion was validated by
subsequent quantitative (q)PCR and karyotyping, and
found to encompass 4.29 Mb.
In this study, we surveyed two ASD cohorts compris-
ing subjects from 958 unrelated families to estimate the
frequency of 15q24 deletions in ASD, and mapped
15q24 deletions in these cohorts as a means of
generating a plausible list of genes that may contribute
to the phenotypes associated with the 15q24 deletion
syndrome.
Methods
The study was approved under the guidelines of the
Ministry of Health of Costa Rica, the ethics committee
of the National Children’s Hospital in San José (Hospital
Nacional de Niños, HNN) and the institutional review
board at Mount Sinai School of Medicine in accordance
with the Declaration of Helsinki.
Subjects
Subjects were derived from two datasets: a genetic study
of autism in an isolated founder population in the Cen-
tral Valley of Costa Rica (CVCR) (n = 173) and the Aut-
ism Genetic Resource Exchange (AGRE) cohort
(n = 1336 subjects with ASD from 785 families). The
CVCR study, initiated by one of the authors (LAM),
including recruitment and assessment, has been
described in detail previously [10,11]. This sample com-
prised 153 males and 20 females and all were sporadic
cases (that is, only one affected child in the family).
Families of individuals with a known or possible diagno-
sis of ASD contacted the HNN or were contacted by
the Costa Rican research team (PJG, head). If they
expressed interest in the study, they were formally asked
to participate using establi s h e di n f o r m e dc o n s e n tc r i -
teria. All interviews and examinations took place at the
Neurodevelopmental Unit of the HNN, where parents
were interviewed by an experienced pediatrician (PJG)
using the Autism Diagnostic Interview-Revised (ADI-R)
[12], and the Autism Diagnostic Observation Schedule
(ADOS) [13] was administered. Both assessments were
videotaped for independent scoring by the best estima-
tor (ERM). IQ tests appropriate for the age and level of
verbal communication of the subjects were adminis-
tered, as were the Vineland Adaptive Behavioral Scales
[14]. A complete medical and neurological examination
was performed, including a dermatological examination
under Wood’s lamp. Subjects were assessed for dys-
morphic features and a full panel of photographs was
taken for further evaluation by a clinical geneticist.
Blood samples were taken from subjects and parents for
DNA extraction and transformation into cell lines. The
parents of patient AU008 reported here provided writ-
ten informed consent for publication of clinical data,
including photographs.
The AGRE cohort is a well-characterized sample that
has been used in numerous studies. Recently, the AGRE
cohort was genotyped and analyzed genome-wide for
CNVs [15], and these data were used here to assess the
frequency of 15q24 deletions. The AGRE sample
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were sporadic cases and 494 were from multiplex
families (two or more affected children per family).
Genotyping on oligonucleotide arrays
The CVCR sample was genotyped using NspI2 5 0 K
arrays (Affymetrix, Santa Clara, CA, USA). Genotyping
was carried out at the University of California Los
Angeles DNA Microarray Facility, part of the NIH
Neuroscience Microarray Consortium, using manufac-
turer-recommended procedures for probe generation
and hybridization. Analysis of these microarray data for
CNVs was carried out as described previously [16],
using the dChip software package https://sites.google.
com/site/dchipsoft/.
Analysis of 15q24 CNVs in the AGRE cohort was per-
formed in a subset of subjects that had been genotyped
(Infinium II HumanHap550 BeadChip, Ilumina, Inc.,
S a nD i e g o ,C A )a n dp a s s e ds t r i c tq u a l i t yc o n t r o lp a r a -
meters, as described in detail previously [15].
Cases with apparent deletions were confirmed with array
comparative genomic hybridization (aCGH) and qPCR.
aCGH
Genomic DNA was purified using a commercial kit in
accordance with the instruction manual (DNA Clean &
Concentrator-5 Kit; Zymo Research, Orange, CA, USA).
aCGH was performed on microarrays according to the
manufacturer’s instructions (Agilent SurePrint G3
H u m a nC G H1×1M ;A g i l e n tT e c h n o l o g i e s ,S a n t a
Clara, CA, USA). In brief, 1.5 μg of experimental and
gender-matched referenceD N A s( P r o m e g a ,M a d i s o n ,
WI, USA) were digested with AluIa n dRsaI restriction
endonucleases (Promega) and fluorescently labeled with
cyanine 5-dCTP (Cy-5; experimental) and cyanine 3-
dCTP (Cy-3; reference) using a labeling kit (Genomic
DNA Labeling Kit; Agilent Technologies). Labeled
experimental and reference DNAs were purified, com-
bined, denatured, pre-annealed with Cot-1 DNA (Invitro-
gen, Carlsbad, CA, USA) and blocking reagent (Agilent
Technologies) and hybridized to the microarrays in a
rotating oven (20 rpm) at 65°C for 40 hours. After hybri-
dization and recommended washes, the arrays were
s c a n n e da t3μm resolution with a G2505B Agilent
Microarray Scanner. Images were processed with Feature
Extraction 9.5.1 Software and the data analyzed with
DNA Analytics 4.0 software (both from Agilent Technol-
ogies). Aberrations were identified using the Aberration
Detection Method-1 algorithm with a sensitivity thresh-
old of 6.0 and a data filter that rejected aberrations that
did not include at least 10 probes with a log2 ratio ± 0.25.
qPCR
We used the Universal Probe Library (UPL) system
(Roche, NJ, USA) to perform genomic qPCR in pro-
bands with apparent deletions and their parents, as
described previously [16]. Primers were designed with
ProbeFinder v2.35 software (Roche, http://www.univer-
salprobelibrary.com).
Multiplex ligation-dependent probe amplification
The methylation status of the 15q11-q13 Prader-Willi
syndrome/Angelman syndrome critical region was
assessed by methylation-sensitive multiplex ligation-
dependent probe amplification (MLPA) (ME028 PWS/
AS MLPA kit; MRC-Holland, Amsterdam, the Nether-
lands). The kit contains five probes to assess methyla-
tion status; four are located in SNRPN and one in NDN.
Electrophoresis of PCR products was performed using
an automated sequencer (ABI 3730; Applied Biosystems,
Foster City, CA, USA). MLPA data were analyzed using
GeneMarker 1.70 software (SoftGenetics, State College,
PA, USA).
Results
15q24 microdeletion in a patient from the Costa Rican
cohort
We screened 173 unrelated patients with ASD from
Costa Rica using the Affymetrix 250K single nucleotide
polymorphism (SNP) microarrays and identified a dele-
tion of the 15q23-q24.1 region in a boy with autism,
moderate intellectual disability and mild dysmorphic
features (patient AU008). The deletion encompassed at
least 2.8 Mb (hg18, chr15:69,897,977-72,697,052), par-
tially overlapping the minimal interval of the recurrent
15q24 microdeletion (Figure 1). Analysis of parental
DNA with the 250K SNP arrays revealed that the dele-
tion had occurred de novo in the paternal chromosome
(data not shown). Real-time qPCR experiments con-
firmed the deletion in the patient and showed that the
distal breakpoint was located in the LMANL1 gene,
between intron 1 (deleted) and exon 14 (normal) (Figure
2). High-resolution aCGH was performed to characterize
further the extent of the deletion, revealing a 3.06 Mb
loss (69,837,976-72,896,937) (Figure 3). Neither break-
point coincides with the recently characterized LCRs in
the region [2,3] or with smaller segmental duplications
reported in the UCSC genome browser http://www.gen-
ome.ucsc.edu/ (Figure 1). The distal breakpoint lies
between LCR 15q24B and 15q24C. Therefore, the dele-
tion in this patient would narrow the critical region for
the novel 15q24 microdeletion syndrome from 1.75 Mb
to 766 kb.
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Page 3 of 12Figure 1 Map of the 15q23-q24 deletion interval. Schematic representation of 15q24 microdeletions in patient AU008 and in 13 other
patients with overlapping deletions reported previously [2-6,8,9]. The map shows a 8 Mb region in chromosome 15q23-q25.1 (68,500,000-
76,500,000, hg18). The vertical bars indicate the five previously reported LCRs, 15q24A-E. Other smaller segmental duplications listed in the UCSC
genome browser are shown at the bottom. The minimal critical deletion region identified previously extends 1.75 Mb between LCRs 15q24B
(BP1) and 15q24D (BP2). The atypical distal breakpoint in patient AU008 (red) narrows the critical region to 766 Mb, containing only 15 RefSeq
genes.
Figure 2 qPCR gene dosage of the 15q24-15q24.1 region in family AU008. Genes within the deleted interval and the flanking regions were
targeted with qPCR probes in patient AU008 and both parents. The names of the genes are followed by the number of the UPL probe used.
Data are means ± SEM. A gene dosage ratio of 1 indicates the presence of two alleles and is considered normal; values < 1 indicate a deletion.
The distal breakpoint is located in the LMANL1 gene, between intron 1 (probe 23) and exon 14 (probe 77).
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deletion
This male child (patient AU008) was 5 years and 1
month old at the time of evaluation. Table 1 provides a
summary of the clinical features in the patient compared
with 13 other 15q23-q24 deletion carriers. The patient
was born at term (39 weeks) to a 21-year-old G1P1
mother and a 28-year-old father. The psychiatric history
of the mother’s family was notable for the fact that the
mother’s paternal grandmother, maternal grandfather
and a maternal aunt had beend i a g n o s e dw i t hs c h i z o -
phrenia, and idiopathic intellectual disability had been
reported in a maternal cousin. During pregnancy,
polyhydramnios was detected and the mother was
hospitalized for several days in the sixth month for pre-
eclampsia. Labor was induced with oxytocin; it lasted 6
hours and the delivery was vaginal. At birth, the child
weighed 2.46 kg (fifth percentile), was 48 cm long (25th
percentile) and had a head circumference of 32 cm (fifth
percentile). His Apgar scores were 9 at 1 minute and at
5 minutes after birth. He was described as an irritable
baby during the perinatal period.
The child was able to support his head at 15 days, dis-
played a social smile at 20 days and sat by himself at 6
months. He was able to stand alone at 7 months, but
did not walk alone until 30 months, and was unable to
hop on one foot. Notably, the parents stated that he did
not crawl because he could not tolerate contact with the
floor, and that from 1 month of age onwards, he did not
want to be touched and would become stiff and throw
his head back if someone lifted him in their arms. He
acquired sphincter control at 36 months. He spoke his
first words at 12 months but never developed phrase
speech, eye contact or pointing. The patient had a maxi-
mum vocabulary of 10-20 words but stopped using
words at the age of 4.5 years. At the time of evaluation,
he used only two words.
His parents stated that he had a difficult temper,
threw frequent tantrums, and was very restless and
hyperactive. He also had difficulty falling and staying
asleep. The patient could not modulate his behavior in
emotional situations and displayed aggressive behaviors
towards himself and/or others when happy or sad. He
laughed or cried out of context, and smiled constantly
no matter what his mood. He did not respond when
called, did not make eye contact and did not follow
instructions. He also displayed a multitude of severe
restricted and repetitive behaviors. For example, he
had difficulty adjusting to change of any kind in his
routine or environment. He displayed stereotypies
including clapping and hand flapping, and self-stimu-
lating behaviors including spinning, hitting objects or
looking at his hands for hours. He put objects in his
mouth constantly. He was interested in parts of objects
such as the wheels of cars and made frequent mean-
ingless noises.
Figure 3 aCGH showing a 3.1 Mb deletion at 15q23-q24.1 in patient AU008. Scatterplot (chromosome view) from the 1 × 1 M array using
DNA Analytics software (Agilent Technologies). The X axis represents copy number relative to the control and the Y axis represents location
along chromosome 15. The area enclosed by the dashed box adjacent to the chromosome 15 ideogram is enlarged on the right. Green circles
indicate probes with a log2 ratio ≤ -0.25, red circles denote probes with a log2 ratio ≥ 0.25; black circles are probes that fall in between these
two values.
McInnes et al. Molecular Autism 2010, 1:5
http://www.molecularautism.com/content/1/1/5
Page 5 of 12Table 1 Clinical features in Patient AU008 compared to 13 individuals with 15q24 deletions reported in the literature
Present case 13 previously reported cases Total (%)
Deletion 15q24
Length, MB 3.06 1.7 to 4.3
Inheritance De novo 11 de novo (2 unknown)
Parental origin Paternal 2 paternal, 3 maternal (8 unknown)
Gender M1 1 M , 2 F
Behavioral abnormalities
Developmental delay/ID Moderate ID 13/13 14/14 (100%)
Impaired speech development Language regression; 2 words at 5 y 7/9 8/10 (80%)
ASD Autism 2 ASD, 1 autistic features/13 3/14 (21%)
Developmental regression + 1/12 2/13 (15%)
Happy facial expression Constant smiling 3/12 4/13 (31%)
Hyperactivity + 2/12 3/13 (23%)
Aggressiveness + 2/12 3/13 (23%)
Sleep disturbances + 1/12 2/13 (15%)
Growth
Low birth weight + 4/12 5/13 (38%)
Pesistent growth retardation - 5/12 5/13 (38%)
Obesity - 3/12 3/13 (23%)
Head circumference <3rd percentile - 3/12 3/13 (23%)
Facial dysmorphism + 13/13 14/14 (100%)
High anterior hair line + 8/12 9/13 (69%)
Long narrow face + 4/12 5/13 (38%)
Hypertelorism + 7/12 8/13 (62%)
Broad medial eyebrows + 6/12 7/13 (54%)
Epicanthus + 6/12 7/13 (54%)
Full lower lip + 5/12 6/13 (46%)
Widely spaced teeth + 1/12 2/13 (15%)
Ear abnormalities Protuberant ears 8/12 9/13 (69%)
Facial asymmetry - 4/12 4/13 (31%)
Down-slanting palpebral fissures - 7/12 7/13 (54%)
Deep set eyes - 2/12 2/13 (15%)
Broad nasal base - 4/12 4/13 (31%)
Flaring alae nasi - 3/12 3/13 (23%)
Hypoplastic alae nasi - 2/12 2/13 (15%)
Depressed nasal bridge - 2/12 2/13 (15%)
Long and/or smooth philtrum - 8/12 8/13 (62%)
Small mouth - 3/12 3/13 (23%)
High arched palate - 2/12 2/13 (15%)
Eye abnormalities + 7/12 8/13 (62%)
Nystagmus + 1/12 2/13 (15%)
Strabismus - 6/12 6/13 (46%)
Microphtalmia - 1/12 1/13 (8%)
Anisocoria - 1/12 1/13 (8%)
Digital abnormalities + 10/12 11/13 (85%)
Single palmar crease Right single palmar crease 2/12 3/13 (23%)
Syndactyly Left 2-3 syndactyly of toes 1/12 2/13 (15%)
Clinodactyly - 3/12 3/13 (23%)
Long slender fingers - 2/12 2/13 (15%)
Brachydactyly - 2/12 2/13 (15%)
Abnormal thumbs - 2/12 2/13 (15%)
Small hands - 2/12 2/13 (15%)
Proximally implanted thumbs - 2/12 2/13 (15%)
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age. The parents were interviewed using the ADI-R and
the child was tested with the ADOS module 1 for non-
verbal subjects. Both tests showed that the patient ful-
filled the criteria for autistic disorder. The results from
the ADI-R gave a score of 29 in the reciprocal social
interaction area (cut-off is 10), a score of 12 in the com-
munication area (cut-off for non verbal subjects 7) and
a score of 8 in the restricted, repetitive behavior area
(cut-off 3), with an onset before 36 months (score 3,
cut-off 1). On the ADOS, the patient scored 7 points in
the communication area (autism cut-off 4) and 10
points in the reciprocal social interaction area (autism
cut-off 7), for a total score of 17 points (autism cut-off
12). The Bayley Scales of Infant Development showed a
performance IQ < 50. In the Vineland Adaptive Beha-
vior Scales, the child obtained a score of 46 for commu-
nication, 52 for daily living skills, 48 years for
socialization and 47 for motor skills; the adaptive beha-
vior composite score was 45.
The medical history for this patient is remarkable for
chronic allergic rhinitis, asthma and frequent respiratory
infections. He also required hospitalization for treatment
of several severe dental cavities at the age of 4 years. An
ophthalmic examination revealed congenital nystagmus.
Brainstem auditory evoked potentials were normal.
Computed tomography of the brain revealed minimal
cortical atrophy but no other abnormalities. The child
was evaluated for sinus bradycardia at 3 and 5 years, but
the results of Holter monitoring were normal and there
was no evidence of arrhythmias. A spinal X-ray revealed
slight lumbar scoliosis but was otherwise normal.
Although the patient did not present with typical Angel-
man features, the inappropriate laughter led us to test
him for this syndrome. A 15q11-q13 deletion was ruled
out by the CNV analysis. The methylation status of the
Prader-Willi syndrome/Angelman syndrome critical
region in 15q11-q13 was assessed using methylation-
sensitive MLPA and no abnormalities were observed,
thus ruling out a uniparental disomy or imprinting
defect. Tests were negative for the FRAXA mutation and
there was a normal G-banded karyotype at 550-band
resolution. Routine blood chemistries, full blood count,
and urine analysis were also normal.
On physical examination at 5.1 years, the patient
weighed 17.5 kg (30th percentile), measured 106 cm in
height (21th percentile) and had a head circumference
of 51 cm. He presented with a high anterior hairline,
Table 1: Clinical features in Patient AU008 compared to 13 individuals with 15q24 deletions reported in the literature
(Continued)
Neurological abnormalities
CNS abnormality by MRI/CT Minimal cortical atrophy on CT 4/7 5/8 (63%)
Hypotonia Not reported but probable 8/12 9/13 (69%)
Seizures - 1/12 1/13 (8%)
Genital abnormalities - 8/10 M 8/11 (73%)
Hypospadias - 4/10 M 4/11 (36%)
Micropenis - 4/10 M 4/11 (36%)
Cryptorchidism - 2/10 M 2/11 (18%)
Musculoskeletal abnormalities
Scoliosis Mild scoliosis 4/13 5/14 (36%)
Joint laxity + 7/12 8/13 (62%)
Chest abnormalities - 3/12 3/13 (23%)
Clubfeet -
Other
Polyhydramminos + 0/12 1/13 (8%)
Recurrent infections Recurrent respiratory infections 6/12 7/13 (54%)
Unusual voice - 4/12 4/13 (31%)
Diaphragmatic hernia - 3/13 3/14 (21%)
Inguinal hernia - 3/12 3/13 (15%)
Growth hormone difficency - 2/12 2/13 (15%)
Bowel atresia - 2/12 2/13 (15%)
Hypogonadism - 2/12 2/13 (15%)
Hearing loss - 2/12 2/13 (15%)
Café-au-lait spots - 2/12 2/13 (15%)
CNS, central nervous system; CT, computed tomography; MRI, magnetic resonance imaging.
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folds, hypertelorism, a full lower lip, widely spaced
teeth, and protuberant, posteriorly rotated ears
(Figure 4). The examination was otherwise notable for
t h ep r e s e n c eo far i g h ts i n g l ep a l m a rc r e a s ea n dp a r t i a l
syndactyly of the second and third toes of the left foot.
He also exhibited joint laxity. All other aspects of the
examination, including evaluation of the heart, abdo-
men, genitalia and skin, were normal.
15q24 microdeletions in the AGRE cohort
Our study in the Costa Rican cohort suggested an esti-
mated frequency of 15q24 deletions in ASD of 1 in 173,
but this was a modest sample. For this reason, follow-up
studies were carried out in an independent cohort. We
made use of recent CNV data from 1,336 AGRE cases
(from 785 distinct families) that passed strict quality
metrics for CNV calling [15]. We did not observe any
large (>100 kb) deletions in this cohort across the mini-
mal 15q24 interval as defined by Sharp et al. [2]. We
observed and confirmed only a 108 kb deletion
(73,911,628-74,020,037) at the distal (telomeric) side of
the critical region, encompassing the UBE2Q2 and
FBX022 genes, in two affected brothers, AU058-003 and
AU058-004 (see Additional file 1, Figure S1A). The
deletion was inherited from the healthy father (AU058-
002) and was absent in the mother (AU058-001). The
deletion was confirmed by qPCR (Additional file 1,
Figure S1B). The segregation pattern of this microdele-
tion and the fact that it lies outside the critical region
indicate that it is unlikely to be pathogenic.
Discussion
15q24 microdeletion syndrome
The phenotype of the 15q24 deletion is heterogeneous,
but all 14 cases described to date (including the present
case) have intellectual disability ranging from mild to
severe, and characteristic facial features (Table 1; Addi-
tional File 2), suggesting that the 15q24 deletion pheno-
type may be clinically recognizable [2]. Facial
characteristics include high anterior hairline, broad
medial eyebrows, hypertelorism, downslanted palpebral
fissures, epicanthus, long and smooth philtrum, full
lower lip and abnormal ears. Other common features
include minor digital anomalies (85%), impaired speech
development (80%), genital abnormalities in males
(73%), hypotonia (69%), eye abnormalities such as stra-
bismus and nystagmus (62%), joint laxity (62%) and
recurrent infections (54%). Less commonly reported fea-
tures include low birth weight, growth hormone defi-
ciency, diaphragmatic and inguinal hernias, scoliosis and
other musculoskeletal abnormalities, bowel atresia, hear-
ing loss and major central nervous system abnormalities
(dysplastic corpus callosum with a transected pituitary
stalk, myelomeningocele with hydrocephalus and multi-
ple cysts of the corpus callosum) [2,3,6].
In this study, we detected a 3.06 Mb de novo deletion
of 15q24 of paternal origin in a boy with overlapping
clinical features with the previously reported cases of
15q24 microdeletion, including low birth weight, devel-
opmental delay, distinct facial features, digital, eye and
ear abnormalities, severely impaired language, joint lax-
ity, scoliosis and recurrent respiratory infections. The
association with nystagmus is in agreement with an ear-
lier report [2]. Although hypotonia had never been
described in the present case, he had delayed motor
development, did not walk independently until 30
months and received physical therapy for 4 years, sug-
gesting that he might have been mildly hypotonic. Our
patient had no genital abnormalities, whereas hypospa-
dias, micropenis or crytoptorchism have been reported
in 8 of 10 previously reported males [2-6].
In addition, patient AU008 exhibited classic features
of autism, along with constant smiling and inappropriate
laughter, reminiscent of Angelman syndrome. Of the
four male cases with a microdeletion of 15q24 initially
reported by Sharp et al., three were noted to have
happy facial expressions, whereas the fourth subject was
described as having ‘autistiform’ traits [2]. Review of the
literature identified two other patients with ASD carry-
ing 15q24 deletions, thus adding this microdeletion syn-
drome to the increasing list of rare genomic disorders
involved in the etiology of autism. Smith et al. described
a girl with autism carrying an interstitial deletion of
chromosome 15q originally mapped by FISH to 15q22-
q23 [8]. However, a recent reassessment of this patient
using Affymetrix SNP 6.0 microarrays identified a 3.12
Mb deletion (70.740-73.860 Mb) between LCR15q24A
and 15q24D (Moyra Smith, personal communication).
The girl’s phenotype was very similar to that observed
in our patient; both exhibited classic autism, intellectual
disability, delayed motor development and mild dys-
morphic facial features. In addition, both had language
regression and were nonverbal at the time of evaluation,
they showed prominent mouthing behavior and they
had frequent infections. The second patient with ASD
carrying a 15q24 microdeletion was identified by Mar-
shall et al. in a whole-genome CNV analysis, and limited
clinical information was provided [9]. This child
appeared to have a more severe phenotype, with severe
dysmorphism, severe scoliosis and diaphragmatic hernia
(see Additional File 2). The real frequency of ASD
among 15q24 deletion carriers is unknown, as the
majority of patients reported to date were not formally
evaluated for autism. The fact that only some patients
with 15q24 deletion have ASD is similar to observations
in many other microdeletion and microduplication syn-
dromes, and is part of the variable clinical presentation
McInnes et al. Molecular Autism 2010, 1:5
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ples of where ASD can be part of the phenotype at vary-
ing rates include 15q11-q13 duplication, 22q13 deletion,
Angelman, DiGeorge, Potocki-Lupski and Williams syn-
dromes, to name but a few [17,18]. Other behavioral
traits reported in 15q24 deletions include hyperactivity/
attention deficit-hyperactivity disorder in two patients,
aggressiveness in two and sleep difficulties in one, sug-
gesting that this deletion may confer susceptibility to
other neuropsychiatric disorders.
Although it is difficult to perform detailed genotype-phe-
notype correlations given the limited number of patients
described to date, some observations are beginning to
emerge. Notably, of the 14 cases with deletions of chromo-
some 15q24, 12 are males [2-6,8,9]. This distortion in the
sex ratio raises the possibility that the penetrance may be
influenced by the sex of the individual. Although the phe-
notype in the two females [3,8] does not appear to differ
significantly from that observed in males (see Additional
File 2), the apparently biased sex ratio is intriguing, and
needs to be confirmed as additional patients are reported.
Diaphragmatic hernia has been described in three patients
with deletions involving the LCR15q24A-15q24B interval
[2,5,9], but was not observed in patient AU008 or in four
other patients with deletions affecting the same interval
[3,6,8], suggesting incomplete penetrance.
Frequency of 15q24 microdeletions in ASD
In our study of the Costa Rican sample, we observed
one case of 15q24 microdeletion syndrome in 173 unre-
lated cases ascertained for ASDs. This corresponds to a
f r e q u e n c yo f0 . 5 4 % .T h i sc o m p a r e st oaf r e q u e n c yo f
0.23% (1/427) in the study of Marshall et al. and a fre-
quency of 0% (0/785 unrelated cases) in the AGRE
families. Combining these studies results in an overall
frequency of 15q24 microdeletions in patients ascer-
tained for ASD of 0.14% (2/1385). It should be noted
that both the AGRE cohort [15] and the Canadian
cohort [9] included large proportions of multiplex
families (63% and 44%, respectively). Given that in all
cases where parental samples were available, 15q24
microdeletions have been shown to be de novo,i ti s
likely that rates are higher in simplex families, thus, the
rate of 0.14% should be considered as a lower bound.
The rates observed in samples ascertained for ASD were
in the same order of 15q24 microdeletions observed in
patients ascertained for unexplained intellectual disabil-
ity and congenital anomalies (~0.33%; 4/1200) [2].
Figure 4 Photographs of patient AU008 with a 15q24 microdeletion. Patient AU008 at (left) 5.1 years and (right) 8.10 years of age. Note the
high anterior hairline, long narrow face, broad medial eyebrows, epicanthal folds, hypertelorism, full lower lip, widely spaced teeth and
protuberant ears. Specific consent from the parents was obtained to publish these photographs.
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In the three cases with ASD reported to date, the dele-
tion arose in the paternal chromosome (the present
case; the girl described by Smith et al. [8] (Moyra
Smith, personal communication) and the case reported
by Marshall et al. [9]). By contrast, three of the subjects
described by Sharp et al. [2] (two with happy facial
expression and one with autistic traits), carried deletions
of maternal origin. Parental origin was not determined
in the remaining cases. It is thus unclear at present the
relevance, if any, of the gender of the parent of origin to
the resultant behavioral phenotype, and more informa-
tion is needed. However, it should be noted that no
imprinted genes have been described in the deleted
15q23-q24 interval http://www.geneimprint.com/.
Atypical 15q24 microdeletion breakpoints
Breakpoints of the 15q24 microdeletions described to
date are typically defined by segmental duplications,
which predispose to recurrent chromosomal rearrange-
ments via non-allelic homologous recombination [2-6].
However, both breakpoints in our patient lie outside
these segmental duplications. Similarly, Marshall et al.
[9] reported a subject with ASD carrying a deletion of
15q23-q24.2, with the proximal breakpoint lying outside
the segmental duplications and within the THSD4 gene,
as in the patient described here (Figure 1), and extend-
ing distally to LCR15q24D. However, the breakpoints in
THSD4 appear to be different, at 69.60 Mb (intron 6) in
the subject described by Marshall et al. [9] and at 69.84
Mb (intron 14) in patient AU0008. Finally, one of the
patients described by Sharp et al. (IMR371) had an aty-
pical 15q24 deletion (Figure 1), and precise mapping of
both breakpoints and sequencing of the junction frag-
ment revealed two unique breakpoints that were not
located within repetitive sequences and had no apparent
pairwise homology [2]. The presence of atypical dele-
tions provides an important opportunity to better
understand the genes in the minimal region and their
relationship to phenotype.
Genes in the minimal deletion interval
Despite the varying sizes of the 15q24 deletions
reported, no correlation has been observed between the
extent of the deletion and clinical severity [2-6,8,9]. In
fact, the phenotypic similarities between all patients
suggest that haploinsufficiency of one or several genes
within the minimal deletion interval are responsible for
the syndrome. The molecular characterization of the
atypical deletion in patient AU008 provides a consider-
ably reduced minimal deletion interval, from 1.75 Mb to
766 kb, implicating a reduced number of genes (15 ver-
sus 38 Refseq genes). Of these genes, two have been
implicated in autosomal recessive disorders.
Homozygous mutations in STRA6 result in a multiple
malformation syndrome typically associated with
anophthalmia or microphthalmia [19], the latter also
observed in one patient with 15q24 deletion syndrome
[2]. CYP11A1 codes for the mitochondrial cholesterol
side-chain cleavage enzyme (cytochrome P450scc), cata-
lyzing the first step of steroid biosynthesis leading to
production of glucocorticoids, mineralocorticoids and
sex hormones. Homozygous mutations in this gene can
lead to congenital adrenal insufficiency with disordered
sexual differentiation [20].
In addition to CYP11A1, two other genes involved in
metabolism, CYP1A1 and CYP1A2 [21], are found in the
minimal interval. These genes are involved in the meta-
bolism of endogenous and xenobiotic compounds,
including caffeine, theophylline, acetominophen,
naproxen and many psychiatric drugs (see the updated
list at the Indiana University Drug Interaction table
http://medicine.iupui.edu/clinpharm/ddis/table.asp).
Careful assessment of drug dosing and sensitivity is
therefore warranted in 15q24 deletion carriers. As these
enzymes are also important in the metabolism of xeno-
biotics including environmental toxins, both increased
and decreased sensitivity to such toxins might be
expected (see [21] for review).
Focusing on neural expressed genes, review of the
Allen Brain Atlas http://www.brain-map.org expression
data on these genes for four brain regions (cerebellum,
CB; neocortex, CTX; hippocampal formation, HPF; and
amygdala, AMY) shows very high and ubiquitous staining
for UBL7 and region-specific, high levels of expression of
SEMA7A (CB), ARID3B (CTX, HPF, AMY) and CLK3
(CTX, HPF) (see Additional File 3). Of these, SEMA7A
(semaphorin 7A), is crucial for proper axon tract forma-
tion during embryonic development [22,23] and T-cell-
mediated immune function [24]. SEMA7A binds to
plexin-C1 and to integrin-b1 [25,26]. There is evidence
from knockout mice that the effects of SEMA7A in axon
outgrowth are mediated by integrin-b1 and mitogen-acti-
vated protein kinase signaling pathways, possibly thereby
regulating the actin cytoskeleton [22]. Interestingly,
another member of the semaphorin family, SEMA5A,
was recently implicated in ASDs through gene expression
studies [27] and genome-wide association studies [28].
Ingenuity pathway analysis confirmed significant
association of genes in the minimal interval with several
metabolic processes (drug metabolism, small molecule
biochemistry, protein synthesis, lipid metabolism and vita-
min and mineral metabolism; maximum P values
5.7 × 10-
07 to 1.2 × 10-
05)d r i v e ne n t i r e l yb yt h et h r e e
CYP-family genes. One interesting finding is that PRDM5,
which is a zinc finger protein, binds to seven genes in the
interval (GOLGA6, ISLR2, ISLR, CCDC33, UBL7, ARID3B
and CLK3) and regulates their expression [29], indicating
McInnes et al. Molecular Autism 2010, 1:5
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as yet unidentified common functionality. Disruption of
multiple genes in a common pathway is more likely to
lead to observable phenotypes.
Conclusions
We estimate that 15q24 microdeletions are etiologically
significant in ≥~0.1% of patients with ASDs. The atypi-
cal breakpoints observed in our patient narrow the
minimal region of overlap and identify genes for sequen-
cing in additional patients. The 15q24 microdeletion
appears to be more common in males than females (12
versus 2), and the three patients with ASD reported to
date all have paternally derived deletions; these two pre-
liminary observations deserve further investigation.
Additional file 1: Figure S1. Deletion of the UBE2Q2 and FBX022
genes in 15q24.2 in family au058. (a) Schematic representation of the
15q24 microdeletion identified with the Illumina 500 k SNP microarray in
AGRE Family AU058. The map shows a 860 kb region in chromosome
15q24.2 (hg18 chr15: 73,540,000-74,400,000). The 108 kb deletion was
present in two affected brothers (AU058-003 and AU058-004) and in
their healthy father (AU058-002). The vertical bar indicates the LCR
cluster 15q24D (BP2). Other smaller segmental duplications listed in
UCSC are shown at the bottom. (b) The deletion was confirmed by qPCR
using a probe in the UBE2Q2 gene in the two patients and their father;
the mother (AU058-001) had normal gene dosage. Data represent
mean ± SEM.
Additional file 2: Supplementary Table 1. Detailed clinical features in
the present case and in 13 individuals with 15q24 deletions reported in
the literature.
Additional file 3: Supplementary Table 2. Genes within the 15q24
microdeletion critical interval. Refseq genes in the minimal deletion
interval defined by the atypical deletion in patient AU008.
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